Eritoran and apremilast in hospitalized patients with COVID-19: The REMAP-CAP immune modulation-2 domain
Authors:
- Hiroki SaitoHSHiroki Saito
- Farah Al-BeidhFAFarah Al-Beidh
- Derek AngusDADerek Angus
- Djillali AnnaneDADjillali Annane
- Yaseen ArabiYAYaseen Arabi
- Abigail BeaneABAbigail Beane
- Lindsay BerryLBLindsay Berry
- Scott BerrySBScott Berry
- Zahra BhimaniZBZahra Bhimani
- Janis Best-LaneJBJanis Best-Lane
- Marc BontenMBMarc Bonten
- Charlotte BradburyCBCharlotte Bradbury
Open Access
- 15 September 2026
- journal article
- Published by Elsevier in CMI Communications
- Vol. 3 (4)
Abstract
No abstract availableFunding Information
- Translational Breast Cancer Research Consortium
- University of Pittsburgh
- Japan Science and Technology Agency
- Eisai
- Eisai Canada
- Amgen
This publication has 21 references indexed in Scilit:
- CONSORT 2025 StatementJAMA, 2025
- Transcriptomic profiling of severe and critical COVID-19 patients reveals alterations in expression, splicing and polyadenylationScientific Reports, 2025
- Vitamin C for Patients With COVID-19JAMA, 2023
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialThe Lancet, 2021
- Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19JAMA, 2020
- Longitudinal analyses reveal immunological misfiring in severe COVID-19Nature, 2020
- In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRsJournal of Medical Virology, 2020
- Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet Respiratory Medicine, 2020
- Accumulating evidence for a role of oxidized phospholipids in infectious diseasesCellular and Molecular Life Sciences, 2014
- Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe SepsisJAMA, 2013